Skip to main content
Equibles

Beneficial ownership — 13D / 13G

85,680 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Bay Pond Partners, L.P. RPT Rithm Property Trust Inc. 13G/A 8.87% 2y
WELLINGTON MANAGEMENT GROUP LLP EQH Equitable Holdings, Inc. 13G/A 3.32% 2y
WELLINGTON MANAGEMENT GROUP LLP GPOR Gulfport Energy Corp 13G 5.42% 2y
WELLINGTON MANAGEMENT GROUP LLP EVH Evolent Health, Inc. 13G 7.23% 2y
WELLINGTON MANAGEMENT GROUP LLP GPCR Structure Therapeutics Inc. 13G 9.43% 2y
WELLINGTON MANAGEMENT GROUP LLP GD General Dynamics Corp 13G/A 5.66% 2y
WELLINGTON MANAGEMENT GROUP LLP HLNE Hamilton Lane INC 13G/A 3.88% 2y
WELLINGTON MANAGEMENT GROUP LLP RARE Ultragenyx Pharmaceutical Inc. 13G/A 5.38% 2y
WELLINGTON MANAGEMENT GROUP LLP SOVO Sovos Brands, Inc. Common Stock 13G/A 1.33% 2y
WELLINGTON MANAGEMENT GROUP LLP ETSY Etsy Inc 13G/A 0.55% 2y
WELLINGTON MANAGEMENT GROUP LLP HLIO Helios Technologies, Inc. 13G 7.64% 2y
WELLINGTON MANAGEMENT GROUP LLP EXC Exelon Corp 13G/A 9.37% 2y
WELLINGTON MANAGEMENT GROUP LLP SBCF Seacoast Banking Corp Of Florida 13G 5.35% 2y
WELLINGTON MANAGEMENT GROUP LLP FOLD AMICUS THERAPEUTICS, INC. 13G 5.18% 2y
WELLINGTON MANAGEMENT GROUP LLP HUM Humana Inc 13G/A 4.36% 2y
WELLINGTON MANAGEMENT GROUP LLP PCH PotlatchDeltic Corporation Common Stock 13G 5.41% 2y
WELLINGTON MANAGEMENT GROUP LLP KYMR Kymera Therapeutics, Inc. 13G/A 8.68% 2y
Wellington Trust Company, NA SILC Silicom Ltd. 13G/A 7.12% 2y
WELLINGTON MANAGEMENT GROUP LLP SWAV Shockwave Medical, Inc. Common Stock 13G 6.78% 2y
WELLINGTON MANAGEMENT GROUP LLP SPNT SiriusPoint Ltd 13G 5.25% 2y
WELLINGTON MANAGEMENT GROUP LLP CUBI Customers Bancorp, Inc. 13G 5.46% 2y
WELLINGTON MANAGEMENT GROUP LLP RCKT Rocket Pharmaceuticals, Inc. 13G 9.09% 2y
WELLINGTON MANAGEMENT GROUP LLP MRUS Merus N.V. Common Shares 13G/A 3.48% 2y
WELLINGTON MANAGEMENT GROUP LLP PRFT Perficient Inc 13G 5.6% 2y
WELLINGTON MANAGEMENT GROUP LLP PODD Insulet Corp 13G/A 4.87% 2y
WELLINGTON MANAGEMENT GROUP LLP PWP Perella Weinberg Partners 13G/A 1.69% 2y
WELLINGTON MANAGEMENT GROUP LLP AEP American Electric Power Co Inc 13G 5.52% 2y
Versant Venture Capital VI, L.P. TPST Tempest Therapeutics, Inc. 13D/A 11% 2y
Versant Venture Capital VI, L.P. ALGS Aligos Therapeutics, Inc. 13D/A 1.9% 2y
Pietro Bersani KRBP Kiromic BioPharma, Inc. Common Stock 13D 6.9% 2y
Hok Pan SE NWGL CL Workshop Group Ltd 13G 70.18% 2y
Bransfield, Kyle P. APCA AP Acquisition Corp 13D 33.7% 2y
Lior Susan OWLT Owlet, Inc. 13D/A 61.1% 2y
WRAPMANAGER INC AAXJ iShares Trust 13G/A 5.47% 2y
Teck Lim Chia BANL CBL International Ltd 13G 52.7% 2y
Brio Capital Master Fund Ltd. PRSO Peraso Inc. 13G 9.97% 2y
Point72 Asset Management, L.P. ANRO Alto Neuroscience, Inc. 13G 6.3% 2y
Ancora Advisors LLC GPRE Green Plains Inc. 13D/A 7% 2y
Orin Hirschman IMMX Immix Biopharma, Inc. 13G 5.8% 2y
Fosun International Ltd LANV Lanvin Group Holdings Ltd 13D/A 58.65% 2y
STILWELL JOSEPH WHLR Wheeler Real Estate Investment Trust, Inc. 13D/A 49.99% 2y
Saba Capital Management, L.P. ECAT BlackRock ESG Capital Allocation Term Trust 13D/A 25.24% 2y
ICAHN CARL C DAN DANA Inc 13D/A 9.9% 2y
ICAHN CARL C BHC Bausch Health Companies Inc. 13D/A 9.51% 2y
Anson Funds Management LP VIEW View, Inc. Class A Common Stock 13D/A 9.9% 2y
CoyCo GP, L.L.C. RCM R1 RCM Inc. Common Stock 13D/A 32.4% 2y
HORIZON KINETICS ASSET MANAGEMENT LLC TPL Texas Pacific Land Corp 13D/A 16.69% 2y
Saba Capital Management, L.P. HQL abrdn Life Sciences Investors 13D/A 8.26% 2y
Lind Global Fund II LP SINT Sintx Technologies, Inc. 13G 9.9% 2y
MASTERCARD FOUNDATION ASSET MANAGEMENT CORP MA Mastercard Inc 13G 10.5% 2y